Advertisement

The Role of the Implantable Cardiac Defibrillator in the Management

  • Olaf Hedrich
  • Gianfranco Buja
  • Domenico Corrado
  • Mark S. Link
  • Thomas Wichter
  • N. A. Mark EstesIII

Abstract

The management of patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) has evolved considerably over the last several years. Because many patients with ARVC/D may be at risk for sudden cardiac death (SCD) and clinical series have reported favorable outcomes with this therapy, the implantable cardioverter-defibrillator (ICD) has assumed a larger role in therapy. On the basis of collective observations from several series of patients, implantation of an ICD in a patient with ARVC/D has a major impact on decreasing the risk of SCD. This chapter examines the available clinical information regarding ICD therapy in patients with ARVC/D.

Keywords

Sudden Death Sudden Cardiac Death Ventricular Cardiomyopathy Implantable Cardiac Defibrillator Arrhythmogenic Right Ventricular Dysplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Calkins H, Marcus F (2003) Arrhythmogenic right ventricular dysplasia. In: Braunwald E, (ed) Harrison’s Advances in Cardiology. McGraw-Hill, New York, pp 378–383Google Scholar
  2. 2.
    Fontaine G, Fontaliran F, Frank R (1998) Arrhythmogenic right ventricular cardiomyopathies: Clinical forms and main differential diagnoses. Circulation 97:1532–1535PubMedGoogle Scholar
  3. 3.
    Corrado D, Thiene G, Nava A et al (1990) Sudden death in young competitive athletes: Clinicopathologic correlations in 22 cases. Am J Med 89:588–596PubMedCrossRefGoogle Scholar
  4. 4.
    Kullo IJ, Edwards WD, Seward JB (1995) Right ventricular dysplasia: The Mayo Clinic experience. Mayo Clin Proc 70:541–548PubMedCrossRefGoogle Scholar
  5. 5.
    Tabib A, Loire R, Chalabreysse L et al (2003) Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation 108:3000–3005PubMedCrossRefGoogle Scholar
  6. 6.
    Maron BJ, Shirani J, Polac L et al (1996) Sudden death in young competitive athletes: Clinical, demographic and pathological profiles. JAMA 276:199–204PubMedCrossRefGoogle Scholar
  7. 7.
    Thiene G, Nava A, Corrado D et al (1988) Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 318:129–133PubMedCrossRefGoogle Scholar
  8. 8.
    Hulot JS, Jouven X, Empana JP et al (2004) Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 110:1879–1884PubMedCrossRefGoogle Scholar
  9. 9.
    Lemola K, Brunckhorst C, Helfenstein U et al (2005) Predictors of adverse outcome in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: Long term experience of a tertiary care centre. Heart 91:1167–1172PubMedCrossRefGoogle Scholar
  10. 10.
    Corrado D, Leoni L, Link MS et al (2003) Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 108:3084–3091PubMedCrossRefGoogle Scholar
  11. 11.
    Link MS, Wang PJ, Haugh CJ et al (1997) Arrhythmogenic right ventricular dysplasia: Clinical results with implantable cardioverter defibrillators. J Intervent Card Electrophysiol 1:41–48CrossRefGoogle Scholar
  12. 12.
    Tavernier R, Gevaert S, De Sutter J et al (2001) Long term results of cardioverter-defibrillator implantation in patients with right ventricular dysplasia and malignant ventricular tachyarrhythmias. Heart 85:53–56PubMedCrossRefGoogle Scholar
  13. 13.
    Roguin A, Bomma C, Nasir K et al (2004) Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 43:1843–1852PubMedCrossRefGoogle Scholar
  14. 14.
    Wichter T, Paul M, Wollmann C et al (2004) Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy. Single-center experience of long-term follow-up and complications in 60 patients. Circulation 109:1503–1508PubMedCrossRefGoogle Scholar
  15. 15.
    Hodgkinson KA, Parfrey PS, Bassett AS et al (2005) The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol 45:400–408PubMedCrossRefGoogle Scholar
  16. 16.
    Wichter T, Breithardt G (2005) Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy. A role for genotyping in decision-making? J Am Coll Cardiol 45:409–411PubMedCrossRefGoogle Scholar
  17. 17.
    McKenna WJ, Thiene G, Nava A et al (1994) Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Br Heart J 71:218–228CrossRefGoogle Scholar
  18. 18.
    Sarter BH, Finkle JK, Gerszten RE et al (1996) What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction? J Am Coll Cardiol 28:122–129PubMedCrossRefGoogle Scholar
  19. 19.
    Grimm W, Flores BF, Marchlinski FE (1993) Complications of implantable cardioverter therapy: Follow-up of 241 patients. Pacing Clin Electrophysiol 16:218–222PubMedCrossRefGoogle Scholar
  20. 20.
    Molina JE (1996) Perforation of the right ventricle by transvenous defibrillator leads: Prevention and treatment. Pacing Clin Electrophysiol 19:288–292PubMedCrossRefGoogle Scholar
  21. 21.
    Dorwarth U, Frey B, Dugas M et al (2003) Transvenous defibrillation leads: High incidence of failure during long-term follow-up. J Cardiovasc Electrophysiol 14:38–43PubMedCrossRefGoogle Scholar
  22. 22.
    Gregoratos G, Abrams J, Eptein AE et al for the ACC/AHA/NASPE Taskforce on Practice Guidelines (2002) Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices. Available at: http://www.acc.org/clinical/guidelines/pacemaker/index.htm. Accessed 3/1/06
  23. 23.
    Priori SG, Aliot E, Blomstrom-Lundqvist C et al (2001) Task Force Report Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 22:1374–1450PubMedCrossRefGoogle Scholar
  24. 24.
    Zipes DP, Camm AJ, Borggrefe M et al (2006) ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 27:2099–2140PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2007

Authors and Affiliations

  • Olaf Hedrich
    • 1
  • Gianfranco Buja
    • 2
  • Domenico Corrado
    • 2
  • Mark S. Link
    • 1
  • Thomas Wichter
    • 3
  • N. A. Mark EstesIII
    • 4
  1. 1.Cardiac Arrhythmia ServiceTufts-New England Medical CenterBostonUSA
  2. 2.Department of Cardiological, Thoracic and Vascular SciencesUniversity of PaduaItaly
  3. 3.Department of Cardiology and AngiologyUniversity Hospital of MünsterMünsterGermany
  4. 4.New England Cardiac Arrhythmia Center, Tufts-New England Medical CenterTufts University School of MedicineBostonUSA

Personalised recommendations